Announced Thu, 23 Jul · 12:15 IST
Cohance Lifesciences board to consider Q1FY27 results on 5 August
Results View source PDF
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.0%1-day move
₹438.35
prior close
₹428.30
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.1+0.0-0.1-3.0-2.8-3.0———————
Up moveDown movePending
AI summary
Cohance Lifesciences (formerly Suven Pharma) will hold a board meeting on 5 August 2026 to consider and approve unaudited standalone and consolidated financial results for Q1FY27 (quarter ended 30 June 2026). Trading window for designated persons and their immediate relatives remains closed until 7 August 2026.
Likely market impact
Quarterly results expected on 5 Aug. Watch for revenue, margins, and growth outlook in the pharma CDMO business.